Welcome to LAM Therapeutics

Return to News > Collaboration announced for combination study with atezolizumab in non-Hodgkin B-cell lymphoma GUILFORD, Conn.—Nov. 30, 2017-- LAM Therapeutics (LAM), a 4Catalyzer company, adv...

https://lamtherapeutics.com/2017/11/lam-therapeutics-announces-progress-of-its-clinical-portfolio-with-fda-clearance-of-new-trial-in-leukemia-and-advancement-of-clinical-trial-in-lymphoma/

Lymphangioleiomyomatosis (LAM) is a rare lung disease found primarily in women and often affects other organs including lymph nodes and kidneys. LAM is caused by inactivating mutations in the tub...

https://lamtherapeutics.com/2017/10/lymphangioleiomyomatosis-overview-new/

Return to News > Strategy and Portfolio Update GUILFORD, Conn., March 30, 2017 – LAM Therapeutics, a 4Catalyzer company that develops drugs for cancer and rare diseases, announced that it has c...

https://lamtherapeutics.com/2017/03/lam-therapeutics-announces-close-of-58m-series-c-financing-and-new-clinical-program-in-cancer/

Return to News > Bringing the total raised for the current class of 4Catalyzer companies to a quarter-billion dollars GUILFORD, Conn. –Feb. 2, 2016– LAM Therapeutics closed a $40 million fina...

https://lamtherapeutics.com/2016/02/lam-therapeutics-closes-40m-in-financing-and-announces-two-clinical-stage-programs-in-rare-diseases-and-cancer/

Return to News > Company is first to focus on developing drugs for Lymphangioleiomyomatosis Guilford, CT – June 6, 2013 – LAM Therapeutics, the first biopharmaceutical company dedicated to id...

https://lamtherapeutics.com/2013/06/lam-therapeutics-launches-operations-to-develop-drugs-for-rare-lung-disease-lymphangioleiomyomatosis-lam/